A method is provided for treating
androgen receptor-associated conditions such as age-related diseases, for example
sarcopenia, employing a compound of the structure wherein R1 is CN or H; X is O or S;R2 is
alkyl or substituted
alkyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl,
aryl or substituted
aryl, or heteroaryl or substituted heteroaryl; R3 and R4 are the same or different and are independently selected from H, C(O)R2a,
alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl,
aryl or substituted aryl, or heteroaryl or substituted heteroaryl; R2a is alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl or substituted heteroaryl; G is aryl or heteroaryl, or aryl or heteroaryl substituted with one, two, three, four or five, where possible, of the substituents selected from the group consisting of
hydrogen (H), halo, NO2, CN, OR2b, OH, CF3, NR3aR4a; wherein R3a and R4a, and R2b are the same or different and are independently selected from alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl and substituted heteroaryl; or a pharmaceutically acceptable salt thereof and a
prodrug ester thereof.